Skip to main content

Table 3 Demographic Data and Pharmacokinetic Parameter Estimates for Montelukast

From: Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics

Subject No.

Age

(yr)

Dose

(mg/kg)

Weight

(kg)

Ka

(1/hr)

Vd/F

(L/kg)

Kel

(1/hr)

1

13

0.188

53.3

0.532

0.08

0.334

3

14

0.166

60.2

0.577

0.06

0.399

5

10

0.293

34.1

0.609

0.14

0.475

7

14

0.125

80.1

0.545

0.09

0.354

8

13

0.272

36.7

0.555

0.11

0.386

9

9

0.22

45.4

0.498

0.11

0.293

10

11

0.305

32.8

0.553

0.13

0.396

11

14

0.14

71.2

0.554

0.10

0.375

12

11

0.305

32.8

0.507

0.14

0.354

13

16

0.176

56.9

0.544

0.14

0.401

14

15

0.187

53.6

0.535

0.13

0.369

15

15

0.169

59.1

0.570

0.10

0.396

17

10

0.173

57.7

0.538

0.11

0.355

19

11

0.152

65.6

0.546

0.08

0.353

20

13

0.223

44.8

0.548

0.13

0.394

21

15

0.115

87.3

0.565

0.11

0.395

22

14

0.19

52.6

0.605

0.08

0.424

23

15

0.123

81.2

0.538

0.09

0.345

Mean (SD)

12.9 (2.1)

0.20 (0.06)

55.9 (16.7)

0.55 (0.03)

0.11 (0.02)

0.38 (0.04)